Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

• Jesús García-Donas ^[14] ; Guillermo de Velasco ^[1] ; Rodrigo Madurga ^[2] ; Jesús Chamorro ^[3] ; Diana Rosero ^[3] ; Olatz Etxaniz ^[15] ; Jose Luis Pérez Gracia ^[4] ; Álvaro Pinto ^[5] ; Diego Cacho ^[6] ; María Barba ^[14] ; Pablo Borrega ^[16] ; Martín Lázaro ^[7] ; Laura Rodriguez ^[8] ; Laura Villalobos ^[9] ; Lourdes García ^[17] ; Andrés Cuellar ^[10] ; María Pilar Solís Hernández ^[11] ; Amalia González ^[12] ; Cristina Pernau ^[13] ; Juan Francisco Rodríguez Moreno ^[14]
  1. [1] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  2. [2] Universidad Francisco de Vitoria

     Universidad Francisco de Vitoria

     Pozuelo de Alarcón, España

     
  3. [3] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  4. [4] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  5. [5] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  6. [6] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  7. [7] Hospital Álvaro Cunqueiro

     Hospital Álvaro Cunqueiro

     Vigo, España

     
  8. [8] Hospital de Fuenlabrada

     Hospital de Fuenlabrada

     Fuenlabrada, España

     
  9. [9] Hospital Universitario Príncipe de Asturias

     Hospital Universitario Príncipe de Asturias

     Alcalá de Henares, España

     
  10. [10] Institute Catalá Oncología

      Institute Catalá Oncología

      Barcelona, España

      
  11. [11] Hospital Universitario Central de Asturias

      Hospital Universitario Central de Asturias

      Oviedo, España

      
  12. [12] Hospital Virgen de la Salud

      Hospital Virgen de la Salud

      Toledo, España

      
  13. [13] Hospital Severo Ochoa

      Hospital Severo Ochoa

      Madrid, España

      
  14. [14] HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid, Spain
  15. [15] Hospital Germá Trials I Pujol, Barcelona, Spain
  16. [16] Hospital Universitario de Cáceres, Cáceres, Spain
  17. [17] Hospital de Segovia, Segovia, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 3, 2024, págs. 732-738
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Cancer is a risk factor for developing severe COVID19. Additionally, SARS-CoV2 has a special tropism for renal cells and complications like thrombosis or cytokine storm could be enhanced by standard treatments in kidney cancer (i.e., antiangiogenics or immunotherapy). Thus, understanding the impact of COVID19 in patients with this tumor is key for their correct management.

    Methods We designed a retrospective case–control study comparing the outcome of three groups of advanced kidney cancer patients on systemic treatment: cohort A (developed COVID19 while on antiangiogenics), cohort B (developed COVID19 while on immunotherapy) and cohort C (non-infected). Matching factors were age, gender, and treatment.

    Results 95 patients were recruited in 16 centers in Spain from September 2020 to May 2021. Finally, 85 were deemed as eligible (23 cohort A, 21 cohort B, 41 cohort C).

    Patients with COVID required more dose interruptions (25 vs. six) and hospitalizations (10 vs. none) than those without COVID (both p = 0.001). No difference between cohorts A and B was observed regarding hospitalization or length of stay. No ICU admission was registered and one patient in cohort B died due to COVID19. Regarding cancer evolution, three patients in cohort A presented progressive disease after COVID19 compared to two in cohort B. One case in cohort B, initially deemed as stable disease, achieved a partial response after COVID19.

    Conclusions Kidney cancer patients who developed COVID19 while on systemic therapy required more treatment interruptions and hospitalizations than those non-infected. However, no significant impact on cancer outcome was observed. Also, no difference was seen between cases on antiangiogenics or immunotherapy.